相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
Jovan P. Antovic et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels
E. M. Hawes et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations
Helen Mani et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2013)
Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2013)
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples
Greg Hapgood et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays Which Assay Is Helpful?
Joyce Curvers et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Joachim Stangier et al.
BLOOD COAGULATION & FIBRINOLYSIS (2012)
Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Walter Ageno et al.
CHEST (2012)
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
Jean-Pierre Bassand
EUROPACE (2012)
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
A. John Camm et al.
EUROPEAN HEART JOURNAL (2012)
UPLC MS/MS assay for routine quantification of dabigatran - A direct thrombin inhibitor - In human plasma
Xavier Delavenne et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)
Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
Menno V. Huisman et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories
L. M. Asmis et al.
THROMBOSIS RESEARCH (2012)
Laboratory assessment of new anticoagulants
Meyer M. Samama et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
Job Harenberg et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor
Richard C. Becker et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
Pancras C. Wong et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement
Genevieve Freyburger et al.
THROMBOSIS RESEARCH (2011)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors
Andreas Calatzis et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
Harry R. Buller et al.
BLOOD (2008)
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
Joachim Stangier
CLINICAL PHARMACOKINETICS (2008)
Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry
G. Rohde
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2008)
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
Joachim Stangier et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients:: a population model analysis
Karl-Heinz Liesenfeld et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Ecarin chromogenic assay - A new method for quantitative determination of direct thrombin inhibitors like hirudin
U Lange et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)
分享论文
